We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ADIMEDI PREGABALIN; ADIMIS PREGABALIN; ADIRAG PREGABALIN; ADIRAMEDICA PREGABALIN; ADIRIS PREGABALIN; ADRABALIN PREGABALIN; ADRANURO PREGABALIN; ADRAPREGA PREGABALIN (AdiraMedica Pty Ltd)
Product name
ADIMEDI PREGABALIN; ADIMIS PREGABALIN; ADIRAG PREGABALIN; ADIRAMEDICA PREGABALIN; ADIRIS PREGABALIN; ADRABALIN PREGABALIN; ADRANURO PREGABALIN; ADRAPREGA PREGABALIN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
148 (255 working days)
Active ingredients
pregabalin
Registration type
New generic medicine
Indication
ADIMEDI PREGABALIN; ADIMIS PREGABALIN; ADIRAG PREGABALIN; ADIRAMEDICA PREGABALIN; ADIRIS PREGABALIN; ADRABALIN PREGABALIN; ADRANURO PREGABALIN; ADRAPREGA PREGABALIN (capsule) is indicated for the treatment of neuropathic pain in adults.
Pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.